NYSE - Delayed Quote USD

Annovis Bio, Inc. (ANVS)

2.1400
+0.0200
+(0.94%)
At close: 4:00:02 PM EDT
2.1400
0.00
(0.00%)
After hours: 7:20:18 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
25,167.8020
26,694.9280
45,035.0110
25,511.2790
14,500.4670
Operating Income
-25,167.8020
-26,694.9280
-45,035.0110
-25,511.2790
-14,500.4670
Net Non Operating Interest Income Expense
-1,377.8960
-1,521.3400
667.8980
182.7120
13.3350
Other Income Expense
-2,514.7990
3,625.8930
-11,837.2000
--
--
Pretax Income
-29,060.4970
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Net Income Common Stockholders
-29,060.4970
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Average Dilution Earnings
3,072.7990
-3,625.8930
0
--
--
Diluted NI Available to Com Stockholders
-25,987.6980
-28,216.2680
-56,204.3130
-25,328.5670
-14,487.1320
Basic EPS
-2.24
-2.02
-6.23
-3.10
-1.90
Diluted EPS
-2.24
-2.31
-6.23
-3.10
-1.90
Basic Average Shares
13,884.0170
12,182.4750
9,023.1380
8,162.3260
7,626.2780
Diluted Average Shares
13,887.0600
12,235.4440
9,023.1380
8,162.3260
7,626.2780
Total Operating Income as Reported
-25,167.8020
-26,694.9280
-45,035.0110
-25,511.2790
-14,537.2210
Total Expenses
25,167.8020
26,694.9280
45,035.0110
25,511.2790
14,500.4670
Net Income from Continuing & Discontinued Operation
-29,060.4970
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Normalized Income
-26,545.6980
-28,216.2680
-44,367.1130
-25,328.5670
-14,487.1320
Interest Income
475.2930
331.8490
667.8980
182.7120
13.3350
Net Interest Income
-1,377.8960
-1,521.3400
667.8980
182.7120
13.3350
EBIT
-25,167.8020
-26,694.9280
-45,035.0110
-25,511.2790
-14,500.4670
EBITDA
-25,167.8020
-26,694.9280
-45,035.0110
-25,511.2790
-14,500.4670
Net Income from Continuing Operation Net Minority Interest
-29,060.4970
-24,590.3750
-56,204.3130
-25,328.5670
-14,487.1320
Total Unusual Items Excluding Goodwill
-2,514.7990
3,625.8930
-11,837.2000
--
--
Total Unusual Items
-2,514.7990
3,625.8930
-11,837.2000
--
--
Normalized EBITDA
-22,653.0030
-30,320.8210
-33,197.8110
-25,511.2790
-14,500.4670
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 1/29/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AVXL Anavex Life Sciences Corp.
7.53
-10.78%
 
SAVA Cassava Sciences, Inc.
2.2400
+8.21%
 
INMB INmune Bio, Inc.
7.68
-1.16%
 
ANNX Annexon, Inc.
2.1000
+0.48%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.0400
+16.85%
 
ACIU AC Immune SA
1.7500
+0.57%
 
CGTX Cognition Therapeutics, Inc.
0.3382
+2.48%
 
BLUE bluebird bio, Inc.
4.9800
0.00%
 
SCPH scPharmaceuticals Inc.
3.2900
-6.53%
 
CAPR Capricor Therapeutics, Inc.
11.01
+6.17%